Ferrario C - Search Results

1

A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012.

Mamo A, Nogueira MC, Batist G, Palumbo M, Panasci L, Ferrario C, Chaudhury P, Metrakos P, Kavan P. Mamo A, et al. Among authors: ferrario c. Curr Oncol. 2013 Apr;20(2):e107-12. doi: 10.3747/co.20.1271. Curr Oncol. 2013. PMID: 23559877 Free PMC article.

2

Docetaxel plus cyclophosphamide in adjuvant breast cancer.

Ferrario C, Panasci LC. Ferrario C, et al. J Clin Oncol. 2007 Sep 20;25(27):4327; author reply 4327. doi: 10.1200/JCO.2007.11.2839. J Clin Oncol. 2007. PMID: 17878491 No abstract available.

3

Tissue microarrays: emerging standard for biomarker validation.

Hassan S, Ferrario C, Mamo A, Basik M. Hassan S, et al. Among authors: ferrario c. Curr Opin Biotechnol. 2008 Feb;19(1):19-25. doi: 10.1016/j.copbio.2007.10.009. Epub 2007 Dec 3. Curr Opin Biotechnol. 2008. PMID: 18053705 Review.

4

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.

Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, Panasci L, Aloyz R. Amrein L, et al. Among authors: ferrario c. Br J Haematol. 2008 Dec;143(5):698-706. doi: 10.1111/j.1365-2141.2008.07418.x. Br J Haematol. 2008. PMID: 19062342 Free article.

5

Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer.

Ferrario C, Wong A, Gao T, Bouganim N, Aloyz R, Panasci LC. Ferrario C, et al. J Chemother. 2011 Feb;23(1):32-5. doi: 10.1179/joc.2011.23.1.32. J Chemother. 2011. PMID: 21482492

6

An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.

Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, Malcolm K, Mousses S, Tonin PN, Basik M. Mamo A, et al. Among authors: ferrario c. Oncogene. 2012 Apr 19;31(16):2090-100. doi: 10.1038/onc.2011.386. Epub 2011 Sep 5. Oncogene. 2012. PMID: 21892209

7

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.

Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, Cohen V, Miller WH Jr, Panasci LC. Sahebjam S, et al. Among authors: ferrario c. Br J Cancer. 2011 Oct 25;105(9):1342-5. doi: 10.1038/bjc.2011.402. Epub 2011 Oct 4. Br J Cancer. 2011. PMID: 21970880 Free PMC article.

8

Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies.

Batist G, Wu JH, Spatz A, Miller WH Jr, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M. Batist G, et al. Among authors: ferrario c. Front Pharmacol. 2011 Oct 5;2:59. doi: 10.3389/fphar.2011.00059. eCollection 2011. Front Pharmacol. 2011. PMID: 22007174 Free PMC article.

9

Advances in the approach to novel drug clinical development for breast cancer.

Ferrario C, Batist G. Ferrario C, et al. Expert Opin Drug Discov. 2014 Jun;9(6):647-68. doi: 10.1517/17460441.2014.911282. Epub 2014 Apr 23. Expert Opin Drug Discov. 2014. PMID: 24758225 Review.

10

Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.

Esfahani K, Ferrario C, Le P, Panasci L. Esfahani K, et al. Among authors: ferrario c. BMJ Case Rep. 2014 Jun 12;2014:bcr2014204287. doi: 10.1136/bcr-2014-204287. BMJ Case Rep. 2014. PMID: 24925537 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

789 results

Search Page

Filters